Sulfonylurea Pharmacotherapy Regimen Adherence in a Medicaid Population: Influence of Age,Gender,and Race

1. Harris MI , Flegal KM , Cowie CC , et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21: 518-524.

2. American Diabetes Association . Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care. 1998;21: 296-309.

3. Tan GH , Nelson RL . Pharmacologic treatment options for non-insulin-dependent diabetes mellitus. Mayo Clin Proc. 1996;71: 763-768.

4. Scheen AJ . Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Drugs. 1997; 54:355-368.

5. Bressler R , Johnson DG . Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157:836-848.

6. Groop LC . Sulfonylureas in NIDDM. Diabetes Care. 1992;15:737-754.

7. Skyler JS . Non-insulindependent diabetes mellitus: a clinical strategy. Diabetes Care. 1984:7: 118-129.

8. Ruoff G . The management of non-insulin-dependent diabetes mellitus in the elderly. J Fam Pract. 1993;36:329-335.

9. Lebovitz HE . Glipizide: a second-generation sulfonylurea hypoglycemic agent: pharmacology, pharmacokinetics and clinical use. Pharmacotherapy. 1985;5:63-77.

10. Feldman JM . Glyburide: a secondgeneration sulfonylurea hypoglycemic agent. Pharmacotherapy. 1985;5: 43-62.

11. Prendergast BP . Glyburide and glipizide: second-generation oral sulfonylurea hypoglycemic agents. Clin Pharm. 1984: 3:473-485.

12. Kaplan R , Davis W . Evaluating the costs and benefits of outpatient diabetes education and nutrition counseling. Diabetes Care. 1984;9:81-86.

13. Irvine AA , Mitchell CM . Impact of communitybased diabetes education on program attenders and non-attenders. Diabetes Educ. 1992;18:29-33.

14. Mason BJ , Matsuyama JR , Jue SG . Assessment of sulfonylurea adherence and metabolic control. Diabetes Educ. 1995;21:52-57.

15. Skaer TL , Sclar DA , Markowski DJ , Won JKH . Effect of value-added utilities on prescription refill compliance and Medicaid health care expenditures: a study of patients with noninsulin dependent diabetes mellitus. J Clin Pharm Ther. 1993;18:295-299.

16. Morris LS , Schulz RM . Medication compliance: the patient's perspective. Clin Ther. 1993;15:593-606.

17. Royal Pharmaceutical Society of Great Britain . From Compliance to Concordance: Achieving Shared Goals in Medicine Taking. London: Royal Pharmaceutical Society of Great Britain; 1997.

18. DeFronzo RA , Goodman AM , and the Multicenter Metformin Study Group . Efficacy of mefformin in patients with noninsulin dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.

19. Ghazzi M , Radke Mitchell L , Venable T , et al, for the Troglitazone Study Group . Troglitazone improves glycemic control in patients with type II diabetes who are not optimally controlled on sulfonylurea [abstract]. Diabetes. 1997;46(suppl 1):44A-44A.

20. Schwarz S , Raskin P , Graveline JF , for the Troglitazone and Exogenous Insulin Study Group . Effect of troglitazone in insulintreated patients with type II diabetes mellitus. N Engl J Med. 1998;338:861-866.

21. Hoffman J , Spengler M . Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The ESSEN Study. Diabetes Care. 1994;17:561-566.

22. Johnson PS , Coniff RF , Hoogwerf BJ , et al. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care. 1994; 17:20-29.

23. Glimepride Multicentre Study Group . Longterm treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res. 1996;28: 419-425.

24. Mullen PD . Compliance becomes concordance: will making a change in terminology produce a change in behaviour? Br Med J. 1997;314: 691-692.